Defining Disease Activity and Response to Therapy in MS
Disease activity in multiple sclerosis (MS) has classically been defined by the occurrence of new neurological symptoms and the rate of relapses. Definition of disease activity has become more refined with the use of clinical markers, evaluating ambulation, dexterity, and cognition. Magnetic resonance imaging (MRI) has become an important tool in the investigation of disease activity. Number of lesions as well as brain atrophy have been used as surrogate outcome markers in several clinical trials, for which a reduction in these measures is appreciated in most treatment studies. With the increasing availability of new medications, the overall goal is to minimize inflammation to decrease relapse rate and ultimately prevent long-term disability. The aim of this review is to give an overview on commonly used clinical and imaging markers to monitor disease activity in MS, with emphasis on their use in clinical studies, and to give a recommendation on how to utilize these measures in clinical practice for the appropriate assessment of therapeutic response.
KeywordsMultiple sclerosis NEDA MRI Lesion
Compliance with Ethical Standards
Conflict of Interest
Mais Al-Kawaz declares no conflict of interest.
Ulrike W. Kaunzner received grant support from Biogen.
Susan A. Gauthier has current grant support from Novartis Pharmaceuticals, Mallinckrodt, and Genzyme.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 19.•• Sormani MP, et al. Assessing response to interferon-beta in a multicenter dataset of patients with MS. Neurology. 2016;87(2):134–40. A pooled data set of 1280 RRMS patients on interferon therapy was analyzed. MRI activity, particularly in combination with clinical relapses within the first year, indicated significant risk of treatment failure and EDSS worsening.CrossRefPubMedGoogle Scholar
- 29.• Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669–76. Meta-analysis evaluating 31 randomized trials using MRI measures and suggesting the use of MRI markers as primary endpoints in future clinical trials.CrossRefPubMedGoogle Scholar
- 55.• Zivadinov, R., et al., A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler. 2016. Study investigating whole brain, white matter and gray matter atrophy, and their effect on clinical disability longitudinally.Google Scholar
- 64.Barkhof F, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in trial assessing injectable interferon vs FTY720 oral in relapsing-remitting multiple sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler. 2014;20(13):1704–13.CrossRefPubMedGoogle Scholar
- 77.•• Rovira A, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11(8):471–82. MAGNIMS (Magnetic Resonance Imaging in MS) network's guidelines on the use of MRI, especially in regards to implementation of brain/spine MRI in the diagnosis of MS.CrossRefPubMedGoogle Scholar
- 84.•• Martinez-Lapiscina EH, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15(6):574–84. A recent meta-analysis assessing peripapillary RNFL in MS patient demonstrating that this measure is predictive of worsening disability.CrossRefPubMedGoogle Scholar
- 86.• Knier, B., et al., Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain. 2016. This study investigated the retinal inner nuclear layer, and suggests that this layer could serve as biomarker to monitor central nervous system inflammation and response to therapy.Google Scholar
- 88.• Giovannoni G, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329–33. This publication suggests the treatment goal of 'no evident disease activity' (NEDA), using clinical parameters and MRI measures.CrossRefPubMedGoogle Scholar
- 94.•• Trojano M, et al. Treatment decisions in multiple sclerosis—insights from real-world observational studies. Nat Rev Neurol. 2017;13(2):105–18. This review focuses on observational studies as 'real world studies', designed to identify predictors of poor outcome and treatment response, and to evaluate the relative and long-term effectiveness of currently available MS medications.CrossRefPubMedGoogle Scholar
- 97.•• Wattjes MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11(10):597–606. MAGNIMS (Magnetic Resonance Imaging in MS) network's guidelines on the use of MRI, especially in regards to predicting treatment response, and in monitoring efficacy and safety of new therapies.CrossRefPubMedGoogle Scholar